eFFECTOR Therapeutics, Inc. (EFTR)
OTCMKTS · Delayed Price · Currency is USD
0.0005
-0.0001 (-16.67%)
Jul 20, 2026, 4:00 PM EST
eFFECTOR Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
2.35K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.55M | 2.12M | 148.46% |
| Dec 31, 2021 | 1.43M | -40.57M | -96.60% |
| Dec 31, 2020 | 42.00M | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitioneFFECTOR Therapeutics News
- 1 year ago - BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board - Newsfile Corp
- 2 years ago - eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq - GlobeNewsWire
- 2 years ago - eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute - TheFly
- 2 years ago - eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewsWire
- 2 years ago - eFfector Therapeutics reports Q1 EPS ($2.16), consensus ($2.16) - TheFly
- 2 years ago - eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 years ago - eFFECTOR Therapeutics to Participate in Upcoming Investor Conference - GlobeNewsWire
- 2 years ago - eFFECTOR Therapeutics trading resumes - TheFly